Content about Bausch & Lomb

ROCHESTER, N.Y. — Bausch + Lomb on Friday announced that it has filed a registration statement with the U.S. Securities and Exchange Commission to take the company public. The number of shares to be offered and the price range for the proposed offering have not yet been determined, the company stated. 

The proposed IPO could raise as much as $1.5 billion and is expected to value Bausch & Lomb at about $9 billion to $10 billion, Reuters reported earlier in March.

ROCHESTER, N.Y. — Bausch + Lomb on Tuesday named Robert Bertolini as president and CFO effective immediately. In this capacity, he will oversee the company's finance, information technology and global quality and operations functions. Bertolini, who assumes CFO responsibilities from Brian Harris, will report to Bausch + Lomb CEO Brent Saunders.  

CHICAGO — Bausch & Lomb is actively exploring a sale that could command upward of $10 billion, according to a report in The Wall Street Journal published Tuesday. 

According to the report, Bausch & Lomb has been entertaining informal inquiries since the announcement that the company may soon issue an initial public offering. If no buyer materializes, the eye care company still plans to pursue an IPO, the report noted.

ROCHESTER, N.Y. — Less than one-third of people take the basic steps necessary to preserve eye sight, according to a Bausch + Lomb global survey released last week. Though if forced to choose, people would rather lose their sense of taste (79%), hearing (78%), one of their limbs (68%) or 10 years off their life (67%) instead of their eyesight.

ROCHESTER, N.Y. — Bausch + Lomb on Friday appointed a clinical professor of ophthalmology to serve as the company's first-ever chief medical officer.

As CMO, Calvin Roberts will coordinate B + L's research and development efforts across its vision care, pharmaceuticals and surgical business units.

In addition to his role at Bausch + Lomb, Roberts is a clinical professor of ophthalmology at Weill Medical College of Cornell University. He also is a member of the board of directors at Alimera Sciences, a biopharmaceutical company he co-founded in 2003.

Bausch & Lomb last month launched the latest innovation in lens care solutions—Biotrue—that is formulated to work like the eyes, with three bio-inspired attributes. Drug Store News caught up with Chris Huels, senior brand manager for lens care at Bausch & Lomb, to talk about the company’s launch plans.

Drug Store News: What is the media plan supporting the launch of Biotrue this fall?